Within- and between-subject biological variation data for tumor markers based on the European Biological Variation Study.

Coşkun A., Aarsand A. K., Sandberg S., Guerra E., Locatelli M., Díaz-Garzón J., ...Daha Fazla

Clinical chemistry and laboratory medicine, cilt.60, ss.543-552, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 60
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1515/cclm-2021-0283
  • Dergi Adı: Clinical chemistry and laboratory medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.543-552
  • Anahtar Kelimeler: biological variation, cancer, tumor markers, CARCINOEMBRYONIC ANTIGEN CEA, HEPATOCELLULAR-CARCINOMA, ANALYTICAL IMPRECISION, REFERENCE INTERVALS, PROGNOSTIC-FACTORS, ALPHA-FETOPROTEIN, SERUM, CANCER, BIOMARKERS, HEALTHY
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Objectives: Reliable biological variation (BV) data are required for the clinical use of tumor markers in the diagnosis and monitoring of treatment effects in cancer. The European Biological Variation Study (EuBIVAS) was established by the EFLM Biological Variation Working Group to deliver BV data for clinically important measurands. In this study, EuBIVAS-based BV estimates are provided for cancer antigen (CA) 125, CA 15-3, CA 19-9, carcinoembryonic antigen, cytokeratin-19 fragment, alpha-fetoprotein and human epididymis protein 4.